Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05798923 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension
A Phase 2 study of Pulmonary Hypertension, sponsored by OrphAI Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 4
- Study locations
NCT05798923: Active Phase 2 study of Pulmonary Hypertension, sponsored by OrphAI Therapeutics.
NCT05798923 is a Phase 2 study of Pulmonary Hypertension that is active but no longer recruiting, run by OrphAI Therapeutics. The registered enrollment target is 10 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (98% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05798923, a Phase 2 study of Pulmonary Hypertension, is active but no longer recruiting, sponsored by OrphAI Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy for the treatment pulmonary hypertension.
Primary Outcome
Change in PVR at 24 weeks
Conditions Studied
Interventions
- DRUG LAM-001
Study Locations (4)
Arizona
- University of Arizona - Tucson
Connecticut
- Yale New Haven Hospital - New Haven
Massachusetts
- Brigham and Women's Hospital - Boston
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
What the registry record for NCT05798923 still lists
NCT05798923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which LAM-001 is the first listed.
NCT05798923 reports a single indexed study location in Arizona, Connecticut, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05798923 about?
NCT05798923 is a clinical study titled "A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension". This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy for the treatment pulmonary hypertension.
What is the current status of trial NCT05798923?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-04-03. Estimated completion is 2027-09-30.
What conditions does trial NCT05798923 study?
This clinical trial studies the following conditions: Pulmonary Hypertension.
What interventions are being tested in trial NCT05798923?
The interventions under investigation include: LAM-001 (DRUG).
Who is sponsoring clinical trial NCT05798923?
This trial is sponsored by OrphAI Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05798923 being conducted?
This trial has 4 study locations across Arizona, Connecticut, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05798923's enrollment target sits among peer trials
10 67th of 72 higher than 4 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
RECRUITING · Phase 2
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI